AbbVie’s $4.5B Skyrizi Growth Rate Slows to 29.2% from 31.9%
BMY•Skyrizi sales rose 29.2% year-over-year to $4.5 billion in the latest quarter, down from 31.9% growth in the prior period. This slight deceleration in the immunology drug’s trajectory could pressure AbbVie’s plan to replace Humira and may prompt investors to reassess its premium valuation.
1. Skyrizi Growth Deceleration
AbbVie reported a 29.2% year-over-year increase in Skyrizi sales to $4.5 billion in the latest quarter, compared with 31.9% growth in the previous period, marking the first noticeable slowdown in the drug’s expansion.
2. Revenue Mix and Guidance Implications
Skyrizi now contributes roughly 30% of AbbVie’s total net revenues, and its deceleration could complicate the company’s ability to meet raised full-year earnings guidance and sustain top-tier growth absent other portfolio drivers.
3. Rising Competitive Pressures
Analysts highlight intensifying competition in the immunology space as a key risk; any further deceleration may signal mounting margin pressure as AbbVie strives to offset Humira’s decline with Skyrizi and Rinvoq.
